This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Petit, T. Articles by Windle, J. J. Search for Related Content PubMed PubMed Citation Articles by Petit, T. Articles by Windle, J. J.

Cancer Therapy and Research Center [T. P., R. M. M., J. J. W.], Departments of Cellular and Structural Biology [D. J. B., J. J. W.] and Pathology [D. A. T.], The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229

⁴ To whom requests for reprints should be addressed, at Massey Cancer Center, Virginia Commonwealth University, P.O. Box 980037, Richmond, VA 23298-0037. Phone: (804) 828-5843; Fax: (804) 828-5836; E-mail: jjwindle{at}hsc.vcu.edu

A transgenic mouse tumor model was used to investigate the role of p53 in tumor response to two different platinum-based chemotherapeutic agents: (a) cisplatin and (b) oxaliplatin, a diaminocyclohexane platine recently introduced into the clinic. MMTV-v-Ha-ras transgenic mice were interbred to p53-deficient mice to generate mice that develop salivary tumors either possessing or lacking p53. Tumor-bearing mice were then treated on either a 9-day schedule to assess overall tumor growth response or on a short-term treatment schedule to assess effects on cell cycle parameters and apoptosis. Both agents induced significant apoptosis and promoted overall tumor regression, regardless of the p53 status of the tumor. This is in contrast to previous studies using this model in which treatment with paclitaxel or doxorubicin promoted tumor growth arrest but not apoptosis. These findings indicate that even in the context of an activated ras gene that potentially mediates suppression of apoptosis, both cisplatin and oxaliplatin are capable of promoting an efficient p53-independent tumor response.